-
Product Insights
NewNet Present Value Model: Armata Pharmaceuticals Inc’s APPA-02
Empower your strategies with our Net Present Value Model: Armata Pharmaceuticals Inc's APPA-02 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Armata Pharmaceuticals Inc’s APSA-02
Empower your strategies with our Net Present Value Model: Armata Pharmaceuticals Inc's APSA-02 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fusion Pharmaceuticals Inc’s FPI-2265
Empower your strategies with our Net Present Value Model: Fusion Pharmaceuticals Inc's FPI-2265 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – APPA-02 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APPA-02 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APPA-02 in Cystic Fibrosis Drug Details: APPA-02 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – APPA-02 in Resistant Pseudomonas aeruginosa Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APPA-02 in Resistant Pseudomonas aeruginosa Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APPA-02 in Resistant Pseudomonas aeruginosa Infections Drug Details: APPA-02 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Nonmelanomatous Skin Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Nonmelanomatous Skin Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Nonmelanomatous Skin Cancer Drug Details: Palbociclib (Ibrance, Agatha) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Marginal Zone B-cell Lymphoma Drug Details: Venetoclax...
-
Product Insights
Resistant Pseudomonas aeruginosa Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Resistant Pseudomonas aeruginosa Infections - Drugs In Development, 2023’, provides an overview of the Resistant Pseudomonas aeruginosa Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Bronchiectasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bronchiectasis - Drugs In Development, 2023’, provides an overview of the Bronchiectasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Klebsiella Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...